Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission

Abstract

Replication-competent (RC) adenoviruses (Ads) are increasingly being developed as oncolytic vectors and as vehicles for delivering vaccine antigens. Although the safety of such vectors in humans is of paramount importance, these vectors pose additional special concerns. Specifically, the prospect of causing Ad-mediated disease in the patient, the amount and sites of Ad replication, the possibility of virus shedding leading to unintended transmission to patient contacts, and the potential for persistence in the inoculated individual must be evaluated. Previous experience with administration of wild-type and RC recombinant Ads to humans may shed light on some of these issues. Experimental infections of humans with natural Ad isolates and RC recombinant vectors show that in adults Ads cause mild or no disease, particularly with Ad serotypes 2 and 5, the serotypes most often used to make recombinant constructs. Other studies show that Ad can replicate in experimentally infected persons, that in some situations Ads can be shed and transmitted to close contacts, and that there is evidence for persistent/latent Ad infection in naturally infected individuals. Overall, these studies indicate that Ads can be safely administered to humans for the treatment of cancer and as antigen delivery vehicles suggesting that the continued development of RC oncolytic and vaccine vectors should be pursued.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Rowe WP, Huebner RJ, Gillmore LK, Parrott RH, Ward TG . Isolation of a cytopathic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med. 1953;84:570–573.

    Article  CAS  PubMed  Google Scholar 

  2. Hilleman MR, Werner JH . Recovery of new agents from patients with acute respiratory illness. Proc Soc Exp Biol Med. 1954;85:183–188.

    Article  CAS  PubMed  Google Scholar 

  3. Huebner RJ, Rowe WP, Ward TG, Parrott RH, Bell JA . Adenoidal—pharyngoconjunctival agents. N Engl J Med. 1954;251:1077–1086.

    Article  CAS  PubMed  Google Scholar 

  4. Horwitz MS . Adenoviruses. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins; 2001: 2301–2326.

    Google Scholar 

  5. Commission on Acute Respiratory Disease. Experimental transmission of minor respiratory illness to human volunteers by filter-passing agents. I. Demonstration of two types of illness characterized by long and short incubation periods and different clinical features. J Clin Invest. 1947;26:957–982.

  6. Bell JA, Ward TG, Huebner RJ, Rowe WP, Suskind RG, Paffenbarger RS . Studies of adenoviruses (APC) in volunteers. Am J Public Health. 1956;46:1130–1146.

    Article  CAS  Google Scholar 

  7. Chaproniere DM, Pereira HG, Roden AT . Infection of volunteers by a virus (A.P.C. type 1) isolated from human adenoid tissue. Lancet. 1956;271:592–596.

    CAS  PubMed  Google Scholar 

  8. Ward TG, Huebner RJ, Rowe WP, Ryan RW, Bell JA . Production of pharyngoconjunctival fever in human volunteers inoculated with APC virus. Science. 1955;122:1086–1087.

    Article  CAS  PubMed  Google Scholar 

  9. Couch RB, Knight V, Douglas Jr RG, Black BH, Hamory SH . The minimal infectious dose of adenovirus type 4; the case for natural transmission by viral aerosol. Trans Am Clin Climatol Assoc. 1969;80:205–211.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Couch RB, Cate TR, Fleet WF, Gerone PJ, Knight V . Aerosol-induced adenoviral illness resembling the naturally occurring illness in military recruits. Am Rev Respir Dis. 1966;93:529–535.

    CAS  PubMed  Google Scholar 

  11. Mitsui Y, Hanabusa J, Minoda R, Ogata S . Effect of inoculating adenovirus (APC virus) type 8 into human volunteers. Am J Ophthalmol. 1957;43:84–90.

    Article  CAS  PubMed  Google Scholar 

  12. Mitsui Y, Hanna L, Minoda R, et al. Experiments in human volunteers with adenovirus type 8. Br J Ophthalmol. 1959;43:540–547.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Jawetz E, Hanna L, Sonne M, Thygeson P . A laboratory infection with adenovirus type 8; laboratory and epidemiologic observations. Am J Hyg. 1959;69:13–20.

    CAS  PubMed  Google Scholar 

  14. Kasel JA, LODA F, Knight V . Infection of volunteers with adenovirus type 16. Proc Soc Exp Biol Med. 1963;114:621–623.

    Article  CAS  PubMed  Google Scholar 

  15. Kasel JA, Evans HE, Spickard A, Knight V . Conjunctivitis and enteric infection with adenovirus types 26 and 27: responses to primary, secondary and reciprocal cross-challenges. Am J Hyg. 1963;77:265–282.

    CAS  PubMed  Google Scholar 

  16. Chanock RM, Ludwig W, Huebner RJ, Cate TR, Chu LW . Immunization by selective infection with type 4 adenovirus grown in human diploid tissue cultures. I. Safety and lack of oncogenicity and tests for potency in volunteers. JAMA. 1966;195:445–452.

    Article  CAS  PubMed  Google Scholar 

  17. Edmondson WP, Purcell RH, Gundelfinger BF, Love JW, Ludwig W, Chanock RM . Immunization by selective infection with type 4 adenovirus grown in human diploid tissue culture. II. specific protective effect against epidemic disease. JAMA. 1966;195:453–459.

    Article  CAS  PubMed  Google Scholar 

  18. Top Jr FH, Buescher EL, Bancroft WH, Russell PK . Immunization with live types 7 and 4 adenovirus vaccines II Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J Infect Dis. 1971;124:155–160.

    Article  PubMed  Google Scholar 

  19. Top Jr FH, Grossman RA, Bartelloni PJ, et al. Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. J Infect Dis. 1971;124:148–154.

    Article  PubMed  Google Scholar 

  20. van der Veen J, Abarbanel MFW, Oei KG . Vaccination with live type 4 adenovirus: evaluation of antibody response and protective efficacy. J Hyg. 1968;66:499–511.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Dudding BA, Bartelloni PJ, Scott RM, Top Jr FH, Russell PK, Buescher EL . Enteric immunization with live adenovirus type 21 vaccine. I. Tests for safety, infectivity, immunogenicity, and potency in volunteers. Infect Immun. 1972;5:295–299.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Scott RM, Dudding BA, Romano SV, Russell PK . Enteric immunization with live adenovirus type 21 vaccine. II. Systemic and local immune responses following immunization. Infect Immun. 1972;5:300–304.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Rosenbaum MJ, De Berry P, Sullivan EJ, et al. Characteristics of vaccine-induced and natural infection with adenovirus type 4 in naval recruits. Am J Epidemiol. 1968;88:45–54.

    Article  CAS  PubMed  Google Scholar 

  24. Couch RB, Chanock RM, Cate TR, Lang DJ, Knight V, Huebner RJ . Immunization with types 4 and 7 adenovirus by selective infection of the intestinal tract. Am Rev Respir Dis. 1963;88 (Suppl-394–403).

  25. Gutekunst RR, White RJ, Edmondson WP, Chanock RM . Immunization with live type 4 adenovirus: determination of infectious virus dose and protective effect of enteric infection. Am J Epidemiol. 1967;86:341–349.

    Article  CAS  PubMed  Google Scholar 

  26. Gaydos CA, Gaydos JC . Adenovirus vaccines in the U.S. military. Mil Med. 1995;160:300–304.

    Article  CAS  PubMed  Google Scholar 

  27. Smith TJ, Buescher EL, Top Jr FH, Altemeier WA, McCown JM . Experimental respiratory infection with type 4 adenovirus vaccine in volunteers: clinical and immunological responses. J Infect Dis. 1970;122:239–248.

    Article  CAS  PubMed  Google Scholar 

  28. Stanley ED, Jackson GG . Spread of enteric live adenovirus type 4 vaccine in married couples. J Infect Dis. 1969;119:51–59.

    Article  CAS  PubMed  Google Scholar 

  29. Mueller RE, Muldoon RL, Jackson GG . Communicability of enteric live adenovirus type 4 vaccine in families. J Infect Dis. 1969;119:60–66.

    Article  CAS  PubMed  Google Scholar 

  30. Schwartz AR, Togo Y, Hornick RB . Clinical evaluation of live, oral types 1, 2, and 5 adenovirus vaccines. Am Rev Respir Dis. 1974;109:233–239.

    CAS  PubMed  Google Scholar 

  31. Lubeck MD, Davis AR, Chengalvala M, et al. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci USA. 1989;86:6763–6767.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Bhat BM, Bhat RA, Chengalvala MV, et al. Comparative analysis of high expression adeno-HBsAg recombinants with and without E3 region proteins in tissue culture, dogs, and chimpanzees. In: Norrby E, Brown F, Chanock RM, Ginsberg HS, eds. Vaccines 94. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1994: 309–314.

    Google Scholar 

  33. Chengalvala MV, Bhat BM, Bhat RA, et al. Replication and immunogenicity of Ad7-, Ad4-, and Ad5-hepatitis B virus surface antigen recombinants, with or without a portion of E3 region, in chimpanzees. Vaccine. 1997;15:335–339.

    Article  CAS  PubMed  Google Scholar 

  34. Lichtenstein DL, Toth K, Doronin K, Tollefson AE, Wold WS . Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol. 2004;23:75–111.

    Article  CAS  PubMed  Google Scholar 

  35. Tacket CO, Losonsky G, Lubeck MD, et al. Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. Vaccine. 1992;10:673–676.

    Article  CAS  PubMed  Google Scholar 

  36. Lubeck MD, Natuk RJ, Chengalvala M, et al. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Res Hum Retroviruses. 1994;10:1443–1449.

    Article  CAS  PubMed  Google Scholar 

  37. Lubeck MD, Natuk R, Myagkikh M, et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med. 1997;3:651–658.

    Article  CAS  PubMed  Google Scholar 

  38. Evans AS . Latent adenovirus infections of the human respiratory tract. Am J Hyg. 1958;67:256–266.

    CAS  PubMed  Google Scholar 

  39. Israel MS . The viral flora of enlarged tonsils and adenoids. J Path Bacteriol. 1962;84:169–176.

    Article  Google Scholar 

  40. Nász I, Tóth M, Lengyel A . Adenoviruses isolated from excised tonsils. Acta Microbiol Acad Sci Hung. 1958;5:267–269.

    PubMed  Google Scholar 

  41. Schlesinger RW . Vagaries of adenovirus-cell complexes. In: Pollard M, ed. Perspectives in Virology. Minneapolis: Burgess; 1961: 69–77.

    Google Scholar 

  42. Strohl WA, Schlesinger RW . Quantitative studies of natural and experimental adenovirus infection of human cells. II. Primary cultures and the possible role of asynchronous viral multiplication in the maintenance of infection. Virology. 1965;26:208–220.

    Article  CAS  PubMed  Google Scholar 

  43. van der Veen J, Lambriex M . Relationship of adenovirus to lymphocytes in naturally infected human tonsils and adenoids. Infect Immun. 1973;7:604–609.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Zaiman E, Balducci D, Tyrrell DA . A.P.C. viruses and respiratory disease in Northern England. Lancet. 1955;269:595–596.

    Article  CAS  PubMed  Google Scholar 

  45. Neumann R, Genersch E, Eggers HJ . Detection of adenovirus nucleic acid sequences in human tonsils in the absence of infectious virus. Virus Res. 1987;7:93–97.

    Article  CAS  PubMed  Google Scholar 

  46. Fox JP, Brandt CD, Wassermann FE, et al. The virus watch program: a continuing surveillance of viral infections in metropolitan New York families VI Observations of adenovirus infections: virus excretion patterns, antibody response, efficiency of surveillance, patterns of infections, and relation to illness. Am J Epidemiol. 1969;89:25–50.

    Article  CAS  PubMed  Google Scholar 

  47. Fox JP, Hall CE, Cooney MK . The Seattle Virus Watch. VII. Observations of adenovirus infections. Am J Epidemiol. 1977;105:362–386.

    Article  CAS  PubMed  Google Scholar 

  48. Green M, Wold WSM, Mackey JK, Rigden P . Analysis of human tonsil and cancer DNAs and RNAs for DNA sequences of group C (serotypes 1, 2, 5, and 6) human adenoviruses. Proc Natl Acad Sci USA. 1979;76:6606–6610.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Horvath J, Palkonyay L, Weber J . Group C adenovirus DNA sequences in human lymphoid cells. J Virol. 1986;59:189–192.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Jones KW, Kinross J, Maitland N, Norval M . Normal human tissues contain RNA and antigens related to infectious adenovirus type 2. Nature. 1979;277:274–279.

    Article  CAS  PubMed  Google Scholar 

  51. Matsuse T, Hayashi S, Kuwano K, Keunecke H, Jefferies WA, Hogg JC . Latent adenoviral infection in the pathogenesis of chronic airways obstruction. Am Rev Respir Dis. 1992;146:177–184.

    Article  CAS  PubMed  Google Scholar 

  52. Elliott WM, Hayashi S, Hogg JC . Immunodetection of adenoviral E1A proteins in human lung tissue. Am J Respir Cell Mol Biol. 1995;12:642–648.

    Article  CAS  PubMed  Google Scholar 

  53. Retamales I, Elliott WM, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med. 2001;164:469–473.

    Article  CAS  PubMed  Google Scholar 

  54. Bateman ED, Hayashi S, Kuwano K, Wilke TA, Hogg JC . Latent adenoviral infection in follicular bronchiectasis. Am J Respir Crit Care Med. 1995;151:170–176.

    Article  CAS  PubMed  Google Scholar 

  55. Macek V, Sorli J, Kopriva S, Marin J . Persistent adenoviral infection and chronic airway obstruction in children. Am J Respir Crit Care Med. 1994;150:7–10.

    Article  CAS  PubMed  Google Scholar 

  56. Macek V, Dakhama A, Hogg JC, Green FH, Rubin BK, Hegele RG . PCR detection of viral nucleic acid in fatal asthma: is the lower respiratory tract a reservoir for common viruses? Can Respir J. 1999;6:37–43.

    Article  CAS  PubMed  Google Scholar 

  57. Marin J, Jeler-Kacar D, Levstek V, Macek V . Persistence of viruses in upper respiratory tract of children with asthma. J Infect. 2000;41:69–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Eissa NT, Chu CS, Danel C, Crystal RG . Evaluation of the respiratory epithelium of normals and individuals with cystic fibrosis for the presence of adenovirus E1a sequences relevant to the use of E1a- adenovirus vectors for gene therapy for the respiratory manifestations of cystic fibrosis. Hum Gene Ther. 1994;5:1105–1114.

    Article  CAS  PubMed  Google Scholar 

  59. Kuwano K, Kawasaki M, Kunitake R, et al. Detection of group C adenovirus DNA in small-cell lung cancer with the nested polymerase chain reaction. J Cancer Res Clin Oncol. 1997;123:377–382.

    Article  CAS  PubMed  Google Scholar 

  60. Kuwano K, Nomoto Y, Kunitake R, et al. Detection of adenovirus E1A DNA in pulmonary fibrosis using nested polymerase chain reaction. Eur Respir J. 1997;10:1445–1449.

    Article  CAS  PubMed  Google Scholar 

  61. Flomenberg P, Piaskowski V, Harb J, Segura A, Casper JT . Spontaneous, persistent infection of a B-cell lymphoma with adenovirus. J Med Virol. 1996;48:267–272.

    Article  CAS  PubMed  Google Scholar 

  62. Flomenberg P, Gutierrez E, Piaskowski V, Casper JT . Detection of adenovirus DNA in peripheral blood mononuclear cells by polymerase chain reaction assay. J Med Virol. 1997;51:182–188.

    Article  CAS  PubMed  Google Scholar 

  63. Garnett CT, Erdman D, Xu W, Gooding LR . Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol. 2002;76:10608–10616.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Smith RR, Huebner RJ, Rowe WP, Schatten WE, Thomas LB . Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 1956;9:1211–1218.

    Article  PubMed  Google Scholar 

  65. Southam CM, Hilleman MR, Werner JH . Pathogenicity and oncolytic capacity of RI virus strain RI-67 in man. J Lab Clin Med. 1956;47:573–582.

    CAS  PubMed  Google Scholar 

  66. Georgiades J, Zielinski T, Cicholska A, Jordan E . Research on the oncolytic effect of APC viruses in cancer of the cervix uteri; preliminary report. Biul Inst Med Morsk Gdansk. 1959;10:49–57.

    CAS  PubMed  Google Scholar 

  67. Zielinski T, Jordan E . [Remote results of clinical observation of the oncolytic action of adenoviruses on cervix cancer]. Nowotwory. 1969;19:217–221.

    CAS  PubMed  Google Scholar 

  68. Shenk T . Adenoviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott, Williams & Wilkins; 2001: 2265–2300.

    Google Scholar 

  69. Balmain A, Gray J, Ponder B . The genetics and genomics of cancer. Nat Genet. 2003;33 (Suppl):238–244.

    Article  CAS  PubMed  Google Scholar 

  70. Coultas L, Strasser A . The role of the Bcl-2 protein family in cancer. Semin Cancer Biol. 2003;13:115–123.

    Article  CAS  PubMed  Google Scholar 

  71. Oren M . Decision making by p53: life, death and cancer. Cell Death Differ. 2003;10:431–442.

    Article  CAS  PubMed  Google Scholar 

  72. Sherr CJ . Principles of tumor suppression. Cell. 2004; 116:235–246.

    Article  CAS  PubMed  Google Scholar 

  73. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373–376.

    Article  CAS  PubMed  Google Scholar 

  74. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;6:879–885.

    Article  CAS  PubMed  Google Scholar 

  75. Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Therapy. 2001;8:746–759.

    Article  CAS  PubMed  Google Scholar 

  76. Reid T, Galanis E, Abbruzzese J, et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Therapy. 2001;8:1618–1626.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM . A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol. 2000;7:588–592.

    Article  CAS  PubMed  Google Scholar 

  78. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001;19:289–298.

    Article  CAS  PubMed  Google Scholar 

  79. Habib NA, Sarraf CE, Mitry RR, et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther. 2001;12:219–226.

    Article  CAS  PubMed  Google Scholar 

  80. Hecht JR, Bedford R, Abbruzzese JL, et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res. 2003;9:555–561.

    CAS  PubMed  Google Scholar 

  81. Hamid O, Varterasian ML, Wadler S, et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:1498–1504.

    Article  CAS  PubMed  Google Scholar 

  82. Makower D, Rozenblit A, Kaufman H, et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res. 2003;9:693–702.

    PubMed  Google Scholar 

  83. Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002;62:6070–6079.

    CAS  PubMed  Google Scholar 

  84. Rudin CM, Cohen EE, Papadimitrakopoulou VA, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol. 2003;21:4546–4552.

    Article  CAS  PubMed  Google Scholar 

  85. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol. 2002;20:1562–1569.

    CAS  PubMed  Google Scholar 

  86. Habib N, Salama H, Abd El Latif Abu Median, et al. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther. 2002;9:254–259.

    Article  CAS  PubMed  Google Scholar 

  87. Ganly I, Kirn D, Eckhardt G, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 2000;6:798–806.

    CAS  PubMed  Google Scholar 

  88. Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Therapy. 2001;8:308–315.

    Article  CAS  PubMed  Google Scholar 

  89. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55 kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000;60:6359–6366.

    CAS  PubMed  Google Scholar 

  90. Nemunaitis J, Cunningham C, Tong AW, et al. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther. 2003;10:341–352.

    Article  CAS  PubMed  Google Scholar 

  91. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR . Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57:2559–2563.

    CAS  PubMed  Google Scholar 

  92. DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001;61:7464–7472.

    CAS  PubMed  Google Scholar 

  93. Yu D-C, Chen Y, Seng M, Dilley J, Henderson DR . The addition of adenovirus type 5 region E3 enables Calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 1999;59:4200–4203.

    CAS  PubMed  Google Scholar 

  94. DeWeese T, Arterbery E, Michalski J, et al. A Phase I/II dose escalation trial of the intra prostatic injection of CG7870, a prostate specific antigen-dependent oncolytic adenovirus in patients with locally recurrent prostate cancer following definitive radiotherapy. Cancer Gene Ther. 2003;10:S13–S14.

    Google Scholar 

  95. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002;62:4968–4976.

    CAS  PubMed  Google Scholar 

  96. Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 2003;63:7497–7506.

    CAS  PubMed  Google Scholar 

  97. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH . A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther. 1998;9:1323–1333.

    Article  CAS  PubMed  Google Scholar 

  98. Benjamin R, Helman L, Meyers P, Reaman G . A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung. Hum Gene Ther. 2001;12:1591–1593.

    CAS  PubMed  Google Scholar 

  99. Matsubara S, Wada Y, Gardner TA, et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res. 2001;61:6012–6019.

    CAS  PubMed  Google Scholar 

  100. Anon. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther. 2002;13:3–13.

  101. Heise CC, Williams AM, Xue S, Propst M, Kirn DH . Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 1999;59:2623–2628.

    CAS  PubMed  Google Scholar 

  102. Lieber A, He CY, Meuse L, et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol. 1997;71:8798–8807.

    CAS  PubMed  PubMed Central  Google Scholar 

  103. Muruve DA, Barnes MJ, Stillman IE, Libermann TA . Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther. 1999;10:965–976.

    Article  CAS  PubMed  Google Scholar 

  104. Yver A . Does detection of circulating ONYX-015 genome by polymerase chain reaction indicate vector replication? J Clin Oncol. 2001;19:3155–3156.

    Article  CAS  PubMed  Google Scholar 

  105. Nemunaitis J, Cunningham C . Does detection of circulating ONYX-015 genome by polymerase chain reaction indicate vector replication? J Clin Oncol. 2001;19:3156–3157.

    Article  Google Scholar 

  106. Peters AH, Drumm J, Ferrell C, et al. Absence of germline infection in male mice following intraventricular injection of adenovirus. Mol Ther. 2001;4:603–613.

    Article  CAS  PubMed  Google Scholar 

  107. Ye X, Gao GP, Pabin C, Raper SE, Wilson JM . Evaluating the potential of germ line transmission after intravenous administration of recombinant adenovirus in the C3H mouse. Hum Gene Ther. 1998;9:2135–2142.

    Article  CAS  PubMed  Google Scholar 

  108. Paielli DL, Wing MS, Rogulski KR, et al. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol Ther. 2000;1:263–274.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr Dorota Skowyra for the Polish to English translation of reference number 67. This work was supported by Grants CA081829, CA108335, CA108046, and CA108046 from the National Institutes of Health.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to William S M Wold.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lichtenstein, D., Wold, W. Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther 11, 819–829 (2004). https://doi.org/10.1038/sj.cgt.7700765

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700765

Keywords

  • adenovirus
  • replication-competent vectors
  • human
  • clinical trials
  • review

This article is cited by

Search

Quick links